Commentary

Development of an alternative animal model to investigate host-microbe interactions

Anna M. Seekatz

Biological Sciences, Clemson University, 190 Collins St, LSF 157A, Clemson, SC 29634, United States

ARTICLE INFO

Article history:
Received 15 October 2019
Accepted 15 October 2019
Available online 8 November 2019

Keywords:
Faecal microbiota transplantation
Animal models
Colitis

In this article of EBioMedicine, Lleal et al. characterise a rat model of colitis to investigate the role of the gut microbiota, the indigenous microbes in the gastrointestinal tract, in colitis [1]. The authors demonstrate two concepts that aid this line of investigation: 1) they establish an alternative model to mice to study inflammatory bowel disease (IBD), and 2) establish efficacy of a single administration of faecal microbiota transplantation (FMT) from a human source in their model, showing that it attenuates disease. They therefore present an alternative animal model for studying host-microbe interactions that may better model the human microbiota.

IBD is a complex gastrointestinal condition defined by chronic inflammation that includes Crohn’s Disease (CD) and Ulcerative Colitis (UC). Although direct aetiology is unknown, disruption of the gut microbiota likely plays a key role. Both alterations to the microbiota structure and overall loss of microbial diversity have been observed in patients with IBD [2], prompting interest in developing microbial therapeutics to cure or alleviate symptoms. One such treatment, faecal microbiota transplantation (FMT), has been used to treat IBD, particularly UC, with some success [3,4]. FMT has been highly effective against infections caused by the healthcare-associated bacterium, Clostridiodes (Clostridium) difficile, acting to restore colonization resistance against the pathogen.

Despite success in using FMT to treat CDI, there has been limited success in using FMT for other gastrointestinal conditions such as IBD and non-gastrointestinal conditions like metabolic syndrome or autism [5]. Reasons for this include disease complexity, issues in donor matching, or selection of target microbes, which have not been clearly delineated for each condition. Additionally, the long-term consequences of FMT are unknown, and compatibility of the recipient and donor microbiota may be important. It is likely that FMT is not a one-size-fits-all treatment, thus impacting individuals differently depending on the condition being treated. Recent studies in humans have attempted to characterize how FMT functions by tracking colonization of microbes or restored functions. Variable colonization following FMT has been observed for certain patient populations [6,7]. Although strain colonization has not been conducted in patients with IBD, where ongoing inflammation may further complicate FMT efficacy, it has been suggested that donor selection plays a role in successful outcome in patients with IBD [4].

Animal models provide the ability to design interventions not possible in human studies that test specific hypotheses. A common method of modeling animals in a more human context includes “humanising” the microbiota of animals, where human microbiota from different patients can be transplanted into germ-free animals. Mice with humanised microbiota from patients with IBD, for instance, have been demonstrated to harbor increased intestinal Th17 and decreased regulatory T cells that exacerbate colitis [8]. One limitation with these studies is the difference between mouse and human microbiota; while the microbiota at a broad taxonomic level may be interchangeable, studies have demonstrated strain-level and functional differences between the microbiota of mice and humans, such as differences in their bile acid capability [9].

The availability of an animal model that more strongly reflects human microbiota is a welcome addition to the field, and Lleal et al. present a case for inclusion of other animals to study human microbes. The authors demonstrate that transplantation of human faecal material was increased and more sustained in rats compared to mice. They then go on to use these “humanised” rats in a model

DOI of original article: 10.1016/j.ebiom.2019.10.065
E-mail address: aseekat@clemson.edu

https://doi.org/10.1016/j.ebiom.2019.10.027
2352-3964/© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
of colitis, reflective of IBD. Rats subsequently treated with FMT from human donors fared significantly better than untreated rats, exhibiting not only changes in their microbiota reflective of the human donor material, but also demonstrating decreased inflammation and histopathology.

Questions still remain about the superiority of a rat model to study host-microbe interactions. The availability of ample comparative data and different genetic backgrounds continue to make mice an attractive model. As the authors mention, the current study used 16S rRNA gene sequencing to compare the microbiota, which is not sufficient to establish strain- or gene-level differences. Additionally, only one mouse population was used in this study. It is known that even mice from the same genetic background can harbor variable microbiota depending on the source, potentially impacting study outcome [10]. Studies that compare mouse populations and focus on differences at the gene or functional level would strengthen rat vs. human microbiota comparisons. Finally, the authors did not compare disease outcome of FMT from rats or mice in their rat model. It is possible that using the host’s own source of FMT would attenuate colitis even further, providing a parallel control of FMT where the host and microbes are “matched” to ascertain if this is important.

Going forward, it is necessary to recognize that conclusions from one disease system, and perhaps microorganisms, are not necessarily interchangeable with another. For there to be success with FMT and related therapies, both models and human studies are required to identify targeted microbial functions as well as determine treatment efficacy, safety, and long-term consequences. The current study provides a useful model and perspective that may aid these lines of inquiry.

Author’s contribution

AMS reviewed the article and related literature, interpreted results, and wrote the commentary.

Declaration of Competing Interest

Dr. Seekatz has nothing to disclose.

Acknowledgments

Apologies to the researchers not cited in the commentary due to space limitations. AMS is supported by NIDDK grant K01-DK11794.

References

[1] L leuk M, Willamil J, Santiago A, Pozuelo M, Manichaek C. A single fecal microbiota transplantation modulates the microbiome and improves clinical manifestations in a rat model of colitis. EBioMedicine 2019. doi: 10.1016/j.ebiom.2019.10.002.
[2] Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014;15(3):382–92. Mar 12.
[3] Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 2017;389(10075):1218–28. Mar 25.
[4] Allegretti J, Eysenbach LM, El-Nachef N, Fischer M, Kelly C, Kassam Z. The current landscape and lessons from fecal microbiota transplantation for inflammatory bowel disease: past, present, and future. Inflamm Bowel Dis Oct 2017;23(10):1710–17.
[5] Wortelboer K, Nieuwdorp M, Herrema H. Fecal microbiota transplantation beyond clostridiodes difficile infections. EBioMedicine Jun 2019;44:716–29.
[6] Smillie CS, Sauk J, Gevers D, et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe 2018;23(2):229–40. Feb 14e225.
[7] Li SS, Zhu A, Benes V, et al. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 2016;352(6285):586–9. Apr 29.
[8] Britton CJ, Contijoch EJ, Mogno I, et al. Microbiotas from humans with inflammatory bowel disease alter the balance of gut Th17 and RDgammat(+) regulatory T cells and exacerbate colitis in mice. Immunity 2019;50(1):212–24. Jan 15e214.
[9] Wallstrom A, Kovatcheva-Datchary P, Stahlman M, Khan MT, Backhed F, Marschall HU. Induction of farnesoid x receptor signaling in germ-free mice colonized with a human microbiota. J Lipid Res Feb 2017;58(2):412–19.
[10] Hildebrand F, Nguyen TL, Brinkman B, et al. Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. Genome Biol 2013;14(1):R4. Jan 24.